FibroBiologics (STU:SG0) FCF Yield % : -2.45 (As of May. 24, 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, FibroBiologics's Trailing 12-Month Free Cash Flow is €-8.39 Mil, and Market Cap is €341.86 Mil. Therefore, FibroBiologics's FCF Yield % for today is -2.45%.

The historical rank and industry rank for FibroBiologics's FCF Yield % or its related term are showing as below:

STU:SG0' s FCF Yield % Range Over the Past 10 Years
Min: -3.72 Med: 0 Max: 0
Current: -2.45

STU:SG0's FCF Yield % is ranked better than
78.25% of 1554 companies
in the Biotechnology industry
Industry Median: -14.35 vs STU:SG0: -2.45

FibroBiologics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

FibroBiologics FCF Yield % Historical Data

The historical data trend for FibroBiologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics FCF Yield % Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

FibroBiologics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial				-	-	-	-	-4.50

Competitive Comparison of FibroBiologics's FCF Yield %

For the Biotechnology subindustry, FibroBiologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroBiologics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroBiologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where FibroBiologics's FCF Yield % falls into.

FibroBiologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

FibroBiologics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-6.324	/	0
	=	N/A%

FibroBiologics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-3.94	*	4	/	350.09437
	=	-4.50%

FibroBiologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

FibroBiologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of FibroBiologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (STU:SG0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

FBLG:USA

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (STU:SG0) Headlines

No Headlines